Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 |
| clinicaltrials |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 30, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03392571 | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients | withdrawn | Phase 2 | 0 | Pancreatic Cancer Research TeamOTHER | 0 | May 7, 2019 | clinicaltrials |
| NCT02967770 | Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer(PanCAN) | withdrawn | Phase 2 | 0 | Georgetown UniversityOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT00386399 | Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer | withdrawn | Phase 2 | 0 | Galectin Therapeutics Inc.INDUSTRY | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT01895790 | Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01045941 | Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2016 | clinicaltrials |
| NCT01473303 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jun 28, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT01598584 | Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 28, 2015 | clinicaltrials |
| NCT02310971 | Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas | withdrawn | Phase 2 | 0 | Prima BioMed LtdINDUSTRY | 0 | Apr 3, 2015 | clinicaltrials |
| NCT01130701 | A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .(PMABIIS) | withdrawn | Phase 2 | 0 | University of Massachusetts, WorcesterOTHER | 1 | Mar 17, 2015 | clinicaltrials |
| NCT01859182 | Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2014 | clinicaltrials |
| NCT00005591 | Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Dec 13, 2013 | clinicaltrials |
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01600807 | OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT01017822 | Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 0 | Jun 24, 2013 | clinicaltrials |
| NCT00487851 | Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer | withdrawn | Phase 2 | 0 | Karolinska InstitutetOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00713687 | Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma(GemOx-PDT) | withdrawn | Phase 2 | 0 | Technical University of MunichOTHER | 1 | Aug 10, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2019source: clinicaltrials